Significance of thyroperoxidase and thyroglobulin antibodies in medically treated Graves’ disease
Authors' conclusion
In GD patients treated with a first course of ATD in a B+R regimen we observed lower titers of TgAb at the end of treatment in patients who relapsed and a significant protection against TED in patients with positive TgAb at diagnosis, irrespectively of TPOAb.
Study context
- Population
- Patients with newly diagnosed Graves' disease (GD) (2000–2022) treated with anti-thyroid drugs (ATD) in a block-and-replace (B+R) regimen for ≥12 months, followed ≥1 year after ATD discontinuation or until relapse
- Participants
- 136 patients
- Exposure
- TPOAb- and TgAb-positive vs -negative patients
- TgAb-positiven = 73
- TgAb-negativen = 63reference
- Outcome
- Antibody prevalence at diagnosis
- Follow-up
- Diagnosis
Main finding
As reported in the abstract
TPOAb positive
98 out of 136
72%
TgAb positive
73 out of 136
54%
Observational data: associations, not effects.
Further findings
TED at diagnosis · less TED with TgAb-positive
P = 0.012
- TED at diagnosis — TPOAb presence at diagnosis not associated with TED
- P = 0.354
Relapse risk by TPOAb or TgAb presence at diagnosis
- Presence of TPOAb did not influence risk of relapse
- P = 0.304
- Presence of TgAb did not influence risk of relapse
- P = 0.348
Factors associated with TED (multivariate logistic regression)
- Absence of TgAb at diagnosis
- P = 0.05
- Time to euthyroidism
- P = 0.009
- Smoking and TRAb levels not associated
TPOAb and TgAb levels during and after treatment as predictors of relapse
- Not predictive of relapse, except lower TgAb titers at 18 months in patients who relapsed
- P = 0.034
Original publication
Significance of thyroperoxidase and thyroglobulin antibodies in medically treated Graves’ disease. Eur Thyroid J. Published 30 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →